2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 243-245
Treatment Considerations, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Clinical Practice (Health Services and Quality), Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Immunology, Autoimmune Disorders, Research, Clinical Research, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

1087 Real-world clinical outcomes and economic outcomes associated with the timing of caplacizumab initiation in acute immune-mediated thrombotic thrombocytopenic purpura in the United States

Shruti Chaturvedi Jr, MBBS, MS, Sylvie Bozzi, MS2, Antonio Oliveira-dos Santos, MD, PhD3, Patrice Gabriel, PharmD4, Kalyani Hawaldar, MS5, Natalia Petruski-Ivleva, PhD6, Gandarvaka Miles7
1 Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States
2 Sanofi, Gentilly, France
3 Sanofi, Sao Paulo, Brazil
4 Sanofi, Cambridge, Massachusetts, United States
5 Sanofi, Washington DC, United States
6 Sanofi, Cambridge, Massachusetts, United States
7 Sanofi, Morristown, New Jersey, United States

Introduction: Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) is characterized by thrombotic microangiopathy (TMA), triggered by inhibitory autoantibodies to von Willebrand factor (vWF) cleaving enzyme (ADAMTS13), resulting in ischemia and organ damage. Caplacizumab, an anti–vWF humanized nanobody, binds to vWF and inhibits platelets adhesion. As a current treatment option for iTTP, caplacizumab has been associated with improved clinical outcomes, including shorter remission time, reduced duration of hospitalization, fewer exacerbations, and lower healthcare resource utilization (HCRU), compared with plasma exchange (PEX) and immunosuppressive therapy alone. This study aims to investigate the clinical and economic outcomes of early versus delayed caplacizumab treatment in real-world clinical practice in the United States (US).

Methods: This retrospective, observational cohort study used data from the Premier Healthcare Database in the US, during the period July 1, 2018, to March 31, 2025. Index date was defined as date of PEX initiation during patient identification period (January 21, 2019–March 31, 2025). Patients aged ≥12 years with a TMA diagnosis (International Classification of Diseases [ICD]-10-CM code M31.1) who received PEX therapy and caplacizumab during an iTTP episode were included. Patients diagnosed with conditions that mimic iTTP during hospitalization or diagnosed with malignancy, or systemic lupus erythematosus, or had organ stem cell transplant were excluded. Treatment patterns, clinical outcomes, HCRU and associated costs were compared between patients who received caplacizumab as early treatment (≤3 days from the start of PEX; Group 1) and those who received delayed treatment (>3 days from the start of PEX; Group 2) during the in-hospital period. Continuous variables were analyzed using t-test (means) and Mood’s median test (medians). Categorical variables were analyzed using chi-squared test or Fisher’s exact test.

Results: Among 243 patients with iTTP who met the study eligibility criteria, 161 received early caplacizumab treatment and 82 received delayed treatment. The median (interquartile range [IQR]) age was 49.0 (35.0–61.0) years in Group 1 and 43.0 (30.0–56.8) years in Group 2. Most patients were female (66.5% in Group 1 and 74.4% in Group 2).

Early caplacizumab treatment was associated with better clinical outcomes and lower HCRU. Fewer Group 1 patients experienced a bleeding event during hospitalization compared to Group 2 patients (27.3% vs. 43.9%; p=0.01). In-hospital mortality was low in both groups (0.6% in Group 1 vs. 3.7% in Group 2; p=0.11). Duration of PEX therapy was lower in Group 1 than in Group 2 (median [IQR]: 5.0 [3.0–7.0] vs. 11.0 [8.0–14.0] days; p<0.001). Duration of caplacizumab treatment was similar between the two groups (median [IQR]: 8.0 [6.0–11.0] days in Group 1 vs. 7.0 [4.0–11.0] days in Group 2; p=0.18). Median hospital duration was lower among patients who received early vs. delayed treatment (median [IQR]: 11.0 [8.0–15.0] days in Group 1 vs. 20.0 [16.0–25.8] days in Group 2; p<0.001). Lower intensive care unit (ICU) utilization was observed in Group 1 compared with Group 2 (42.9% vs. 56.1%; p=0.07).

Early caplacizumab treatment was also associated with lower cost overall despite similar caplacizumab costs between groups (p=0.52). The median total inpatient hospital charges per patient were $32,432.91 lower in Group 1 than in Group 2 (Median [IQR]: $121,987.01 [$82,535.64–$174,966.98] vs. $154,419.92 [$112,575.41–$211,702.10]; p=0.01). PEX−related charges were lower in Group 1 compared with Group 2, with a difference in medians of $11,082.31 (median [IQR]: $13,599.38 [$7,534.20–$23,197.46] vs. $24,681.69 [$15,561.30–$39,509.35]; p<0.001). The median charges associated with all other services and therapies were also lower in Group 1 by $29,139.35 (median [IQR]: $36,462.30 [$24,703.15–$52,315.52] vs. $65,601.65 [$47,672.65–$95,950.82]; p<0.001).

Conclusions: Early versus delayed initiation of caplacizumab was associated with better clinical outcomes, reduced HCRU, and substantial cost savings during hospitalization. 

Patrice Gabriel, PharmD: Sanofi - Current holder of stock options in a privately-held company; Sanofi - Current Employment